Sector News

DSM Managing Board re-appointments

March 19, 2015
Life sciences
Royal DSM, the global Life Sciences and Materials Sciences company, today announces the proposed re-appointment of Stephan B. Tanda as member of the DSM Managing Board at the upcoming Annual General Meeting of Shareholders (AGM) on 30 April 2015. DSM also announces the departure of DSM Managing Board member Stefan Doboczky per 1 June 2015.
The transformation of the DSM pharmaceutical activities was completed in 2014, and DSM now holds participations in two joint ventures. As a result, it has been agreed between DSM and Stefan Doboczky that his term as a Managing Board member will not be renewed at the upcoming AGM. Stefan will leave DSM per 1 June  and has accepted employment outside of DSM.
Stefan Doboczky has worked in DSM’s Pharma businesses for 17 years and has, as a Managing Board member, successfully led the design and execution of the Pharma strategy, resulting in the creation of DSM Sinochem Pharmaceuticals (DSP, Antibiotics JV with Sinochem) and DPx (Pharma JV with JLL/Patheon).
The responsibilities of Stefan Doboczky will be redistributed among the current Managing Board members.
Feike Sijbesma, CEO and Chairman of the DSM Managing Board, commented: “During the years that Stefan worked for DSM in Pharma and as Regional President in Asia, he spearheaded many strategic growth initiatives that helped transform our business. DSM is very grateful for the contribution he has made over many years and, also on behalf of my colleagues, I wish him every success in the next step in his career.”
Source: DSM

Related News

September 25, 2020

Novo Nordisk tees up phase 3 trial for once-weekly insulin

Life sciences

People with Type 2 diabetes are no strangers to needles, with some injecting bolus insulin after meals, others injecting basal insulin once or twice a day, and others still doing […]

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]